EA200600509A1 - Соединения пиримидотиофена - Google Patents

Соединения пиримидотиофена

Info

Publication number
EA200600509A1
EA200600509A1 EA200600509A EA200600509A EA200600509A1 EA 200600509 A1 EA200600509 A1 EA 200600509A1 EA 200600509 A EA200600509 A EA 200600509A EA 200600509 A EA200600509 A EA 200600509A EA 200600509 A1 EA200600509 A1 EA 200600509A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alk
optionally substituted
hydrogen
group
compounds
Prior art date
Application number
EA200600509A
Other languages
English (en)
Other versions
EA009920B1 (ru
Inventor
Брайан Уильям Димок
Мартин Джеймс Драйсдейл
Кристоф Фромонт
Аллан Джордан
Ксавьер Баррил-Алонсо
Original Assignee
Вернэлис (Кембридж) Лимитед
Кансер Рисеч Текнолоджи Лтд.
Дзе Инститьют Оф Кансер Рисеч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0320300A external-priority patent/GB0320300D0/en
Priority claimed from GB0327924A external-priority patent/GB0327924D0/en
Priority claimed from GB0414467A external-priority patent/GB0414467D0/en
Application filed by Вернэлис (Кембридж) Лимитед, Кансер Рисеч Текнолоджи Лтд., Дзе Инститьют Оф Кансер Рисеч filed Critical Вернэлис (Кембридж) Лимитед
Publication of EA200600509A1 publication Critical patent/EA200600509A1/ru
Publication of EA009920B1 publication Critical patent/EA009920B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Соединения формулы (I) являются ингибиторами активности HSP90 in vitro или in vivo и применимы в лечении среди прочего ракагде Rпредставляет собой группу формулы -(Ar)-(Alk)-(Z)-(Alk)-Q, в которой Arпредставляет собой необязательно замещенный арильный или гетероарильный радикал, Alkи Alkявляются необязательно замещенными двухвалентными C-Салкиленовым или С-Салкениленовым радикалами, m, р, r и s независимо равны 0 или 1, Z представляет собой группу -О-, -S-, -(C=O)-, -(C=S)-, -SO-, -С(=O)O-, -C(=O)NR-, -C(=S)NR-, -SONR-, -NRC(=O)-, -NRSO- или -NR-, в которой Rпредставляет собой водород или C-Салкил и Q представляет собой водород или необязательно замещенный карбоциклический или гетероциклический радикал; Rпредставляет собой водород, необязательный заместитель или необязательно замещенный (C-С)алкильный, арильный или гетероарильный радикал; и Rпредставляет собой сложноэфирную, карбоксамидную или сульфонамидную группу.
EA200600509A 2003-08-29 2004-08-26 Соединения пиримидотиофена EA009920B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0320300A GB0320300D0 (en) 2003-08-29 2003-08-29 Pyrimidothiophene compounds
GB0327924A GB0327924D0 (en) 2003-12-02 2003-12-02 Pyrimidothiophene compounds
GB0414467A GB0414467D0 (en) 2004-06-29 2004-06-29 Pyrimidothiophene compounds
PCT/GB2004/003641 WO2005021552A1 (en) 2003-08-29 2004-08-26 Pyrimidothiophene compounds

Publications (2)

Publication Number Publication Date
EA200600509A1 true EA200600509A1 (ru) 2006-08-25
EA009920B1 EA009920B1 (ru) 2008-04-28

Family

ID=34279360

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600509A EA009920B1 (ru) 2003-08-29 2004-08-26 Соединения пиримидотиофена

Country Status (13)

Country Link
US (2) US7820658B2 (ru)
EP (1) EP1675861B1 (ru)
JP (1) JP4783731B2 (ru)
KR (1) KR101139314B1 (ru)
AU (1) AU2004268820B2 (ru)
BR (1) BRPI0413861A (ru)
CA (1) CA2537135C (ru)
EA (1) EA009920B1 (ru)
ES (1) ES2559779T3 (ru)
HK (1) HK1095591A1 (ru)
NO (1) NO20061416L (ru)
NZ (1) NZ546044A (ru)
WO (1) WO2005021552A1 (ru)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416168D0 (en) * 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006085149A2 (en) * 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EA013522B1 (ru) * 2005-03-30 2010-06-30 Конформа Терапьютикс Корпорейшн Алкинилпирролопиримидины и их применение в качестве ингибиторов hsp90
DE102005022977A1 (de) * 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
CA2633752A1 (en) * 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
US20080004271A1 (en) * 2006-01-17 2008-01-03 Mckenna Jeffrey M Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith
KR20090007319A (ko) * 2006-03-11 2009-01-16 베르날리스 (알 앤드 디) 리미티드 Ｈｓｐ90 억제제로서 사용되는 피롤로피리미딘 유도체
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
HUE064514T2 (hu) 2006-10-12 2024-03-28 Bellus Health Inc Módszerek, vegyületek, kompozíciók és közegek 3-amino-1-propánszulfonsav szervezetbe juttatására
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
WO2008059368A2 (en) * 2006-11-17 2008-05-22 Pfizer Products Inc. Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
CA2675677A1 (en) 2007-02-01 2008-08-07 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
AU2008220009A1 (en) 2007-03-01 2008-09-04 Chugai Seiyaku Kabushiki Kaisha Macrocyclic compound
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
DE102007028521A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
KR101533440B1 (ko) 2007-09-14 2015-07-03 얀센 파마슈티칼스 인코포레이티드 １´,３´-이치환된-４-페닐-３,４,５,６-테트라히드로-２ｈ,１´ｈ-[１,４´]비피리디닐-２´-온
BRPI0817101A2 (pt) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
GB0718433D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
AU2008323287B2 (en) 2007-11-14 2011-07-14 Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
US9567318B2 (en) * 2009-08-17 2017-02-14 Memorial Sloan-Kettering Cancer Center Substituted pyrimidine compounds and uses thereof
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2012282903A1 (en) 2011-07-08 2014-02-13 Sloan-Kettering Institute For Cancer Research Uses of labeled HSP90 inhibitors
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2013266086B2 (en) 2012-05-25 2018-03-01 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
GB201217704D0 (en) * 2012-10-03 2012-11-14 Ucb Pharma Sa Therapeutic agents
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
US20150031697A1 (en) * 2013-07-26 2015-01-29 Wisconsin Alumni Research Foundation Method for preventing ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20220039824A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
AU2015228386A1 (en) * 2014-03-11 2016-09-22 Godavari Biorefineries Limited Cancer stem cell targeting compounds
EP3116882A4 (en) * 2014-03-11 2017-08-02 Godavari Biorefineries Ltd. Compounds for eradicating or inhibiting proliferation of cancer stem cells
JP6607870B2 (ja) 2014-05-13 2019-11-20 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ７０モジュレーターならびにその作製および使用方法
US10023864B2 (en) 2014-06-06 2018-07-17 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
CA2952230C (en) * 2014-06-13 2023-03-21 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
US10945998B2 (en) * 2015-03-08 2021-03-16 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating fibrosis
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15 PGDH INHIBITORS WITH CORTICOSTEROIDS AND / OR TNF INHIBITORS AND USES THEREOF
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
AU2018249956A1 (en) 2017-04-07 2019-11-14 Board Of Regents Of The Univeristy Of Texas Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
PL3904350T3 (pl) * 2018-04-12 2024-02-19 Bayer Aktiengesellschaft Pochodne N-(cyklopropylometylo)-5-(metylosulfonylo)-N-{1-[1-(pirymidyn-2-ylo)-1H-1,2,4-triazol-5-ilo]etylo}benzamidu oraz odpowiednie pochodne pirydyno-karboksyamidu jako pestycydy
WO2022089449A1 (zh) * 2020-10-26 2022-05-05 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用
CN115124550B (zh) * 2020-10-26 2024-04-02 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438261A3 (en) * 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
JPH0578362A (ja) * 1990-01-16 1993-03-30 Takeda Chem Ind Ltd 縮合複素環化合物，その製造法，用途及び中間体
CA2464031A1 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine

Also Published As

Publication number Publication date
EA009920B1 (ru) 2008-04-28
NO20061416L (no) 2006-05-23
WO2005021552A1 (en) 2005-03-10
ES2559779T3 (es) 2016-02-15
AU2004268820A1 (en) 2005-03-10
US8642594B2 (en) 2014-02-04
AU2004268820B2 (en) 2011-07-21
HK1095591A1 (en) 2007-05-11
NZ546044A (en) 2009-09-25
KR20070055414A (ko) 2007-05-30
CA2537135C (en) 2013-10-08
US20070043044A1 (en) 2007-02-22
JP2007533611A (ja) 2007-11-22
US7820658B2 (en) 2010-10-26
BRPI0413861A (pt) 2006-10-24
JP4783731B2 (ja) 2011-09-28
US20100120767A1 (en) 2010-05-13
KR101139314B1 (ko) 2012-04-26
EP1675861A1 (en) 2006-07-05
EP1675861B1 (en) 2015-12-23
CA2537135A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
EA200600509A1 (ru) Соединения пиримидотиофена
EA200701779A1 (ru) Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии
EA200970311A1 (ru) ПРОИЗВОДНЫЕ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-α]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
RS52978B (en) FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS
CY1111083T1 (el) Παραγωγα νικοτιναμιδιου χρησιμα ως αναστολεις της p38
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
ATE377004T1 (de) Proteinkinaseinhibitoren
DE60331187D1 (de) Kinaseinhibitoren
ME00411B (me) Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
EA200870192A1 (ru) Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
TW200635585A (en) Monocyclic substituted methanones
IS6309A (is) Kínasólínafleiður
EA200701780A1 (ru) Противоопухолевое средство
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
EA200501730A1 (ru) Производные n-пирролидин-3-ил-амида в качестве ингибиторов обратного захвата серотонина и норадреналина
CY1109085T1 (el) Νεα αλατα
EA200301100A1 (ru) Новые фталазиноны
EA201000101A1 (ru) Производные пиримидина 934
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU